drugset / Trial / NCT01153386

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386

Phase 1 Completed 36 enrolled United Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare the bioavailability and pharmacokinetics of the 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine tablet strengths in healthy volunteers.

Timeline

Start
2010-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil diethanolamine Unknown 0.5 mg Oral
Subject Treprostinil diethanolamine Unknown 1 mg Oral
Subject Treprostinil diethanolamine Unknown 2.5 mg Oral